• Something wrong with this record ?

Fatty Acid Amide Hydrolase Inhibitor Treatment in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Adaptive Double-blind, Randomized Controlled Trial

FME. Wagenlehner, JWO. van Till, JGA. Houbiers, RV. Martina, DP. Cerneus, JHJM. Melis, A. Majek, E. Vjaters, M. Urban, H. Ramonas, DA. Shoskes, JC. Nickel,

. 2017 ; 103 (-) : 191-197. [pub] 20170227

Language English Country United States

Document type Journal Article, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc18025138

OBJECTIVE: To examine the effect of a peripherally active fatty acid amide hydrolase (FAAH) inhibitor ASP3652 on safety and efficacy outcomes in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Inhibition of FAAH is hypothesized to reduce the excitability of urinary tract afferents including nociceptors. MATERIALS AND METHODS: In this adaptive, randomized, double-blind, placebo-controlled study, adult male patients with moderate to severe CP/CPPS were treated for 12 weeks with an oral dose of ASP3652 (25, 75, 150, or 300 mg twice daily, or 300 mg once daily), or placebo. A Bayesian model was used for adaptive prospective modeling of randomization, study continuation decisions, and analysis of the efficacy variables. RESULTS: The study was stopped for futility at preplanned interim analysis when 239 patients were randomized (226 were included in the intention-to-treat set): the 25 mg group showed the largest reduction of the primary end point National Institutes of Health Chronic Prostatitis Symptom Index total score (7.0 points), but the placebo group showed a mean reduction of 7.3 points (difference: 0.3 [95% confidence interval: -1.9, 2.6]). Micturition outcomes improved compared with placebo in all ASP3652 groups; for example, in the 300 mg twice daily group, voiding frequency decreased by -1.10 (95% CI: -2.0, -0.2) voids/24 hours vs placebo. Safety outcomes were comparable across the treatment groups. CONCLUSION: ASP3652 was generally safe and well-tolerated. It did not show efficacy on pain symptoms in patients with CP/CPPS. However, the results indicate that FAAH inhibition may attenuate lower urinary tract symptoms. Dedicated studies in patients with lower urinary tract dysfunction are needed to confirm this.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18025138
003      
CZ-PrNML
005      
20180719094546.0
007      
ta
008      
180709s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.urology.2017.02.029 $2 doi
035    __
$a (PubMed)28254462
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Wagenlehner, Florian M E $u Clinic for Urology, Pediatric Urology and Andrology, Justus-Liebig-University, Giessen, Germany.
245    10
$a Fatty Acid Amide Hydrolase Inhibitor Treatment in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Adaptive Double-blind, Randomized Controlled Trial / $c FME. Wagenlehner, JWO. van Till, JGA. Houbiers, RV. Martina, DP. Cerneus, JHJM. Melis, A. Majek, E. Vjaters, M. Urban, H. Ramonas, DA. Shoskes, JC. Nickel,
520    9_
$a OBJECTIVE: To examine the effect of a peripherally active fatty acid amide hydrolase (FAAH) inhibitor ASP3652 on safety and efficacy outcomes in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Inhibition of FAAH is hypothesized to reduce the excitability of urinary tract afferents including nociceptors. MATERIALS AND METHODS: In this adaptive, randomized, double-blind, placebo-controlled study, adult male patients with moderate to severe CP/CPPS were treated for 12 weeks with an oral dose of ASP3652 (25, 75, 150, or 300 mg twice daily, or 300 mg once daily), or placebo. A Bayesian model was used for adaptive prospective modeling of randomization, study continuation decisions, and analysis of the efficacy variables. RESULTS: The study was stopped for futility at preplanned interim analysis when 239 patients were randomized (226 were included in the intention-to-treat set): the 25 mg group showed the largest reduction of the primary end point National Institutes of Health Chronic Prostatitis Symptom Index total score (7.0 points), but the placebo group showed a mean reduction of 7.3 points (difference: 0.3 [95% confidence interval: -1.9, 2.6]). Micturition outcomes improved compared with placebo in all ASP3652 groups; for example, in the 300 mg twice daily group, voiding frequency decreased by -1.10 (95% CI: -2.0, -0.2) voids/24 hours vs placebo. Safety outcomes were comparable across the treatment groups. CONCLUSION: ASP3652 was generally safe and well-tolerated. It did not show efficacy on pain symptoms in patients with CP/CPPS. However, the results indicate that FAAH inhibition may attenuate lower urinary tract symptoms. Dedicated studies in patients with lower urinary tract dysfunction are needed to confirm this.
650    _2
$a dospělí $7 D000328
650    _2
$a amidohydrolasy $x antagonisté a inhibitory $7 D000581
650    _2
$a biologická dostupnost $7 D001682
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a monitorování léčiv $x metody $7 D016903
650    12
$a inhibitory enzymů $x aplikace a dávkování $x farmakokinetika $7 D004791
650    _2
$a lidé $7 D006801
650    12
$a symptomy dolních močových cest $x diagnóza $x farmakoterapie $x etiologie $7 D059411
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a pánevní bolest $x diagnóza $x farmakoterapie $x etiologie $7 D017699
650    12
$a prostatitida $x komplikace $x diagnóza $x farmakoterapie $7 D011472
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a van Till, J W Olivier $u Astellas Pharma Europe B.V., Leiden, The Netherlands. Electronic address: olivier.vantill@astellas.com.
700    1_
$a Houbiers, Jos G A $u Astellas Pharma Europe B.V., Leiden, The Netherlands.
700    1_
$a Martina, Reynaldo V $u Biostatistics Department, University of Liverpool, Liverpool, United Kingdom.
700    1_
$a Cerneus, Dirk P $u Astellas Pharma Europe B.V., Leiden, The Netherlands.
700    1_
$a Melis, Joost H J M $u Astellas Pharma Europe B.V., Leiden, The Netherlands.
700    1_
$a Majek, Antoni $u Centrum Medyczne Szpital Sw Rodziny Sp z o.o., Lodz, Poland.
700    1_
$a Vjaters, Egils $u Stradins Clinical University Hospital, Riga, Latvia.
700    1_
$a Urban, Michael $u Androgeos, Praha, Czech Republic.
700    1_
$a Ramonas, Henrikas $u Vilnius University Hospital "Santariskiu Klinikos" Urology Centre, Vilnius, Lithuania.
700    1_
$a Shoskes, Daniel A $u Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH.
700    1_
$a Nickel, J Curtis $u Department of Urology, Queen's University, Kingston, ON, Canada.
773    0_
$w MED00010732 $t Urology $x 1527-9995 $g Roč. 103, č. - (2017), s. 191-197
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28254462 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180719094847 $b ABA008
999    __
$a ok $b bmc $g 1317269 $s 1022059
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 103 $c - $d 191-197 $e 20170227 $i 1527-9995 $m Urology $n Urology $x MED00010732
LZP    __
$a Pubmed-20180709

Find record

Citation metrics

Archiving options